Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.43 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 10/20 | 0.38 |
| ▸ | ACE | P12821 | 9/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759040 | 1.00 | BCL2 (0.43) | BCL2BCL2L2CALCRLMEN1KMT2A | |
| SCHEMBL4377560 | 0.93 | GAA (0.42) | BCL2BCL2L2CALCRLKMT2AL3MBTL1 | |
| SCHEMBL4377559 | 0.93 | GAA (0.42) | BCL2BCL2L2CALCRLKMT2AL3MBTL1 | |
| SCHEMBL6755381 | 0.93 | GAA (0.42) | BCL2BCL2L2CALCRLKMT2AL3MBTL1 | |
| SCHEMBL4383332 | 0.93 | GAA (0.42) | BCL2BCL2L2CALCRLKMT2AL3MBTL1 | |
| SCHEMBL6758457 | 0.86 | CALCRL (0.40) | BCL2BCL2L2CALCRLL3MBTL1GAA | |
| SCHEMBL6761598 | 0.86 | MCL1 (0.43) | BCL2BCL2L2CALCRLL3MBTL1MME | |
| SCHEMBL6761592 | 0.86 | MCL1 (0.43) | BCL2BCL2L2CALCRLL3MBTL1MME | |
| SCHEMBL6758462 | 0.86 | CALCRL (0.40) | BCL2BCL2L2CALCRLL3MBTL1GAA | |
| SCHEMBL6758454 | 0.86 | CALCRL (0.40) | BCL2BCL2L2CALCRLL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-6759424-B2 | 2,5-DIOXOIMIDAZOLIDINE OR 2-THIO-5-OXOIMIDAZOLIDINE DERIVATIVES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| US-6423712-B1 | 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-23 | — | — | US | disclosed |
| EP-0903353-A1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | VCAM1, ITGA1, ITGA4 | BCL2 1892/4885BCL2L2 3088/4885CALCRL 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.